We give a brief comment on the new blood-flow data from Vicore and the recent share price developmen...
Q3 report due on Monday, 17 October Transportation prices coming down, input costs still high 10x ...
I april 2022 tecknade Kiliaro ett avtal med den turkiska mobiltillverkaren Reeder om förinstallering...
Huvudverksamheterna tuffar på och bolaget presterar i höjd med omsättningsmålet.
Redeye endorses that CLS has received FDA clearance for its MR-guided laser ablation system in neuro...
We attended Rovio’s Q3 mid-quarter meeting for sell-side analysts today, which was hosted by IR Timo...
EG7 has announced that it has signed a new agreement to divest Innova which will yield a quicker pay...
Redeye comments on RLS’s directed issue of new shares to Zebra holdings and Investments Limited.
Redeye endorses the new preclinical data presented by Alzecure at IASP, indicating an analgesic and ...
Redeye leaves a comment following Lipum’s announcement yesterday evening of a directed share issue o...
Redeye comments on Sprint Bioscience announcing a rights issue.
Redeye notes that Volvo Car and Polestar are closing in on launching at least one model each but on ...
Ljustillverkaren fortsätter växa omsättningen och under Q2 vänder bolaget dessutom till svarta siffr...
Redeye comments on the milestone reached yesterday and the resulting movement in the share price.
The updated strategy sets the company’s focus back to Finland.
Redeye comments on yesterday's news regarding the CEO shift.
Case reaffirmed; mgmt. confident in ’22 guidance No focus on the risk of JaTak supports our estimat...
Incoming CEO presented at today’s Copenhagen seminar Gas independence strengthens asset quality Po...
Flera faktorer driver fortsatt efterfrågan för solcellstak i en uppåtgående trend.
Portföljbolagen utvecklades väl trots utmanande klimat.
